Clinical trial

Efficacy of Suprazygomatic Approach of Sphenopalatine Ganglion Block for Nasal Surery

Name

ACCA

Description

nasal surgery carries many perioperative challenges, intraoperative bleeing and its effect on surgical field i the main intraoperative concern an postoperative agitation and its serious complications is the main postoperative challenge.

Trial arms

Trial start

2021-11-10

Estimated PCD

2023-12-10

Trial end

2023-12-10

Status

Completed

Treatment

Bupivacaine 0.5% Preservative-Free Injectable Solution

1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach

Arms:

bupivacaine group

normal saline

1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach

Arms:

saline group

Size

110

Primary endpoint

Postoperative emergence agitation

2 hour

Eligibility criteria

Inclusion Criteria: * patient written consent * elective surgery * age 18 - 55 year old Exclusion Criteria: * patient refusal * emergency surgery

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 110, 'type': 'ACTUAL'}}

Updated at

2024-05-28

1 organization

2 products

1 indication

Organization

Product

Indication

Product